INVEST IN

The World’s Smartest Physician is your physician, with Tachyra.

Tachyra is an AI-first clinical decision support platform. Before each visit, it reviews a patient’s history, medications and lab trends, then gives the physician a ranked differential diagnosis, medication-interaction checks, personalized baseline trends and treatment comparisons to review and approve.

Request investor materials Meet the founder

Open to accredited investors only. Verification of accredited status is required before investing.

THE PROBLEM

Diagnostic and medication errors are among the largest sources of preventable harm in medicine.

795,000

U.S. deaths or permanent disabilities each year linked to diagnostic error.

Newman-Toker et al., BMJ Quality & Safety, 2024

~100,000

Emergency hospitalizations of older adults each year from adverse drug events.

Budnitz et al., New England Journal of Medicine, 2011

62.5% → 85.6%

Diagnostic accuracy of individual physicians versus collaborative review on standardized cases.

Barnett et al., JAMA Network Open, 2019

HOW IT WORKS

A second set of eyes before the patient walks in. The physician decides.

Review

Before the visit, Tachyra reads the patient’s history, medication list and lab trends.

Prepare

It prepares a ranked differential, interaction and duplication flags, baseline trends and treatment comparisons, with its reasoning shown.

Physician review and approval

Every recommendation goes through physician review and approval, and every decision is recorded in an audit trail.

WHY TACHYRA

Built for the workflow

Designed to integrate with the EHR systems physicians already use, so help appears where they work, not on another screen.

AI-first, capital-efficient

The working prototype was developed using an AI-first approach, so each dollar raised goes further than in a conventionally staffed build.

Physician in charge

Tachyra never diagnoses or prescribes on its own. Transparent reasoning and a full decision record support physician trust.

AGE IS NO BARRIER

Barry Michaels, DC, MPA

Founder & CEO, age 85

“After 50 years in business, I know which problems are worth solving. AI gave me a way to build the solution myself.”

Barry Michaels has built and run businesses for more than 50 years across healthcare, aviation, publishing and real estate, and is the author of the multi-book healthcare series The Natural Therapies Handbook. At 85, he is leading Tachyra’s development with an AI-first approach.

LEADERSHIP

The team checking every part of the work

Patrick Turley

Chief Financial Officer

Henri A. Ward

Chief Operating Officer

Dhanashree Dorage

VP of Engineering

Annie Casta, MD, FAAFP

Medical Director & VP of Clinical Affairs

Now recruiting: Chief Technology Officer and Chief Medical Officer.

THE OFFERING

InstrumentPost-Money SAFE.

Target raise$6,000,000 (range $5M–$8M)

Valuation capSet in the offering documents.

DiscountSet in the offering documents.

Minimum investment$25000

Eligible investorsAccredited, verified

Where we are today

Working prototype of the decision support engine
Signed leadership team in finance, operations, clinical affairs and engineering
Estimated 9 to 12 months from funding to pilot readiness
Pre-revenue; no pilot results yet

Use of funds

Platform build to pilot readiness, released in milestone stages
Physician pilots and clinical validation
Security, compliance and regulatory work
Completing the leadership team

HOW TO INVEST

Request materials

Email us for the investor packet.

Verify accreditation

Through a CPA or attorney letter, or a verification service.

Review the offering

Access the offering documents and data room.

Sign and fund

Execute the SAFE and transfer funds.

Request the investor packet

info@tachyradiagnostics.com

Email us

Important information

This page is intended for accredited investors. Securities are offered only to verified accredited investors under Rule 506(c) of Regulation D, and only through definitive offering documents. This page is not an offer to sell or a solicitation of an offer to buy any security in any jurisdiction where such an offer would be unlawful.

The securities have not been registered under the Securities Act of 1933 or any state securities law and are subject to restrictions on transfer. Investing in an early-stage company involves a high degree of risk, including the possible loss of the entire investment.

Tachyra is in pilot development. Features described are the platform’s planned capabilities; availability will be confirmed as each is validated. Statements about future plans are forward-looking and may not occur.